These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34247450)

  • 1. Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group.
    Ménard T; Young K; Siegel L; Emerson J; Studt R; Sidor L;
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):799-803. PubMed ID: 34247450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leading a Digital Transformation in the Pharmaceutical Industry: Reimagining the Way We Work in Global Drug Development.
    Finelli LA; Narasimhan V
    Clin Pharmacol Ther; 2020 Oct; 108(4):756-761. PubMed ID: 32294230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 4. Leveraging Industry-Academia Collaborations in Adaptive Biomedical Innovation.
    Stewart SR; Barone PW; Bellisario A; Cooney CL; Sharp PA; Sinskey AJ; Natesan S; Springs SL
    Clin Pharmacol Ther; 2016 Dec; 100(6):647-653. PubMed ID: 27617845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
    Forster SP; Stegmaier J; Spycher R; Seeger S
    Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving models of collaborative drug discovery: managing intellectual capital assets.
    Allarakhia M
    Expert Opin Drug Discov; 2018 Jun; 13(6):473-476. PubMed ID: 29569503
    [No Abstract]   [Full Text] [Related]  

  • 7. Uniting Discovery and Care: The Role of Pharmaceutical Companies in Research, Clinical Studies, and Patient Care.
    Tan C; McGill JM; Mallbris L
    J Invest Dermatol; 2020 Mar; 140(3):527-530. PubMed ID: 31972248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
    Miller J; Ross JS; Wilenzick M; Mello MM
    BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A call for sharing: adapting pharmaceutical research to new realities.
    Munos BH; Chin WW
    Sci Transl Med; 2009 Dec; 1(9):9cm8. PubMed ID: 20368187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taking the pulse of strategic outsourcing relationships.
    Getz KA; Lamberti MJ; Kaitin KI
    Clin Ther; 2014 Oct; 36(10):1349-55. PubMed ID: 25444564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collaborative university-industry R&D practices supporting the pharmaceutical innovation process: Insights from a bibliometric review.
    Ma Z; Augustijn K; de Esch IJP; Bossink B
    Drug Discov Today; 2022 Aug; 27(8):2333-2341. PubMed ID: 35550437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reflections on the Innovative Medicines Initiative.
    Goldman M
    Nat Rev Drug Discov; 2011 May; 10(5):321-2. PubMed ID: 21532547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-Based Monitoring: Key Conditions in Collaboration Between Contract Research Organization and Sponsor.
    Wolfs M; Bambic A; Lange BS; Galante K; Plaza RS; O'Conallain C; Racaro G; Giblin M; Djali S
    Ther Innov Regul Sci; 2019 Jul; 53(4):512-518. PubMed ID: 30157695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health research and innovation: Can we optimize the interface between startups/pharmaceutical companies and academic health care institutions or not?
    Dhainaut JF; Blin O; Herry F; ; Benito S; Bilbault P; Cauterman M; Favrel-Feuillade F; Fazi-Leblanc S; Germain C; Goehrs C; Grosskopf C; Labarthe B; Lechat P; Malciu C; Marquet P; Miceli-Richard C; Peyret O; Rattenbach R; de Saint-Exupéry E
    Therapie; 2020; 75(1):113-123. PubMed ID: 31948660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities for Collaboration at the Interface of Pharmacovigilance and Manufacturing.
    Beninger P
    Clin Ther; 2017 Apr; 39(4):702-712. PubMed ID: 28366594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surmounting structural barriers to tackle endemic infectious diseases.
    Calderón F; Fairlamb AH; Strange M; Williams P; Nathan CF
    J Exp Med; 2021 Sep; 218(9):. PubMed ID: 34410327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategic alliance management: lessons learned from the Bayer-Millennium collaboration.
    Ziegelbauer K; Farquhar R
    Drug Discov Today; 2004 Oct; 9(20):864-8. PubMed ID: 15475317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.